Treatment of Triple Negative Breast Cancer

Introduction to Treatment Guidelines

• The American College of Surgeons and other guideline societies recommend neoadjuvant chemotherapy with pembrolizumab combined with sequential chemotherapy for patients with triple negative breast cancer, followed by surgery and adjuvant radiotherapy 1

Neoadjuvant Treatment

• Neoadjuvant therapy is the standard of care for stage II and III triple negative breast cancer, allowing for reduction of tumor size, evaluation of pathological complete response (pCR), and opportunity to adjust adjuvant therapy based on response 1
• The KEYNOTE-522 protocol demonstrated significant benefit in event-free survival (HR 0.63, 95% CI 0.48-0.82, P<0.001) compared to chemotherapy alone 1
• Pathological complete response (pCR) remains a strong independent prognostic factor regardless of BRCA1/2 germline status 1

Specific Treatment Regimen

• The recommended treatment sequence is paclitaxel + carboplatin + pembrolizumab, followed by doxorubicin + cyclophosphamide + pembrolizumab 1
• Paclitaxel 80 mg/m² IV weekly for 12 consecutive weeks, carboplatin (dose according to institutional protocol), and pembrolizumab 200 mg IV every 3 weeks 1
• Doxorubicin 60 mg/m² IV + cyclophosphamide 600 mg/m² IV every 2 weeks for 4 cycles with G-CSF support, and pembrolizumab continued every 3 weeks 1

Post-Neoadjuvant Surgery

• Surgery should be scheduled 3-4 weeks after the last cycle of chemotherapy to allow for recovery of cell counts 1
• If there is a response to neoadjuvant treatment, consider breast-conserving surgery (lumpectomy) plus level I/II axillary dissection (if sentinel lymph node pre-chemotherapy was not performed or was positive) 2
• If there is no response or minimal response, consider alternative chemotherapy followed by local therapy, usually mastectomy plus axillary dissection 2

Adjuvant Treatment

• Continue pembrolizumab adjuvant regardless of the extent of response to neoadjuvant chemotherapy plus pembrolizumab (whether pCR or residual disease) 1
• Complete up to 1 year of total therapy with pembrolizumab 2
• If there is residual disease post-neoadjuvant, consider capecitabine adjuvant for six to eight cycles if BRCA1/2 germline wild-type 1

Radiotherapy

• After breast-conserving surgery, whole-breast radiotherapy (WBRT) is recommended, with consideration of boost dose to the primary tumor bed in patients at intermediate/high risk 3
• After mastectomy, radiotherapy to the chest wall and supraclavicular lymph nodes is recommended, with consideration of radiotherapy to internal mammary lymph nodes (category 3) 2, 4

Expected Outcomes

• Pathological complete response rates with AC followed by weekly paclitaxel range from 31-41% in triple negative breast cancer 1
• With pembrolizumab-chemotherapy, the pCR rate is 64.8% versus 51.2% with chemotherapy alone 1

Prognostic Considerations

• Young age (38 years) is associated with higher risk of local recurrence after breast-conserving surgery with or without radiotherapy 3
• High Ki67 (90%) indicates a highly proliferative tumor 5
• High histologic grade (Nottingham score 9) confirms aggressive behavior 5

Genetic Considerations

• Family history of breast cancer (grandmother at 55 years, mother at 45 years) and young age (38 years) with triple negative breast cancer justify genetic counseling and testing 6
• BRCA1/2 germline mutation status should be evaluated in patients with HER2-negative metastatic breast cancer as part of routine clinical practice 6
• If BRCA positive, consider bilateral prophylactic mastectomy and increased surveillance for ovarian cancer 3

Guideline for Adjuvant Radiotherapy and Systemic Therapy in Stage IIB Triple‑Negative Breast Cancer

1. Decision‑Making Principles

• The indication for post‑mastectomy radiotherapy (PMRT) must be based on clinical tumor characteristics before neoadjuvant chemotherapy, not on the pathological findings after treatment. The NCCN Guidelines emphasize this principle. [7][8]

• For patients with clinical N1 disease (axillary node ≥10 mm on imaging) even when a biopsy is not performed, the initial nodal status drives the recommendation for PMRT. [7][9]

• A high initial disease burden (e.g., T2 N1) sustains a substantial risk of local‑regional recurrence despite a good pathological response, justifying PMRT. The NCCN Guidelines highlight this risk. 8

2. Indications for Post‑Mastectomy Radiotherapy

• Stage IIB (T2 N1 M0) triple‑negative breast cancer is an absolute indication for PMRT. This classification is derived from pre‑treatment tumor size (3.2 cm) and nodal involvement (11.5 mm node). The NCCN Guidelines list stage IIB as a criterion. 8

• General NCCN‑endorsed indications for PMRT include:

3. Radiotherapy Planning and Dose

• Target volumes should encompass the chest wall and the supraclavicular nodal region; internal mammary nodes should be considered for medial‑located tumors. Evidence from Annals of Oncology supports inclusion of these fields. 10

• Standard dose regimens:

• Boost irradiation (up to 60–66 Gy) may be added for patients with:
  The NCCN Guidelines specify these boost criteria. 8

• Age‑based boost (recommended for patients < 45 years) is not applicable to a 60‑year‑old patient. The NCCN Guidelines define the age threshold. 8

4. Systemic Adjuvant Therapy

• Pembrolizumab should be continued for a total of 1 year from the start of neoadjuvant therapy, regardless of the pathological response. This recommendation follows the Annals of Oncology 2023 evidence. 7

• Capecitabine (6–8 cycles) is advised for patients with residual disease after neoadjuvant therapy (e.g., residual tumor ≈8 mm). The Annals of Oncology data support its use in this setting. 7

• Concurrent administration of pembrolizumab with radiotherapy is permissible and endorsed by the NCCN Guidelines. 8

5. Common Pitfalls to Avoid

• Do not base PMRT decisions solely on postoperative pathology; rely on pre‑treatment staging as mandated by the NCCN Guidelines. [7][8]

• Ensure comprehensive nodal coverage (chest wall + supraclavicular ± internal mammary) rather than irradiating only the chest wall. Annals of Oncology emphasizes appropriate field design. 10

• Do not discontinue pembrolizumab before completing the 1‑year course, even if the pathological response is minimal. Annals of Oncology recommends continuation. 7

• Do not overlook capecitabine for residual disease, as it provides documented survival benefits per Annals of Oncology. 7